Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed non-small cell lung cancer
• * Locally advanced (stage IIIB) or metastatic (stage IV) disease
• * Inoperable disease
• Relapsed or refractory disease
• * Received 1, and only 1, prior chemotherapy regimen for locally advanced or metastatic disease
• Measurable or evaluable disease
• No symptomatic or inadequately treated brain metastases
• No CNS disease
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Karnofsky 70-100%
• Life expectancy
• More than 3 months
• Hematopoietic
• Platelet count greater than 100,000/mm\^3
• Hemoglobin greater than 8.0 g/dL
• Absolute neutrophil count greater than 1,500/mm\^3
• Hepatic
• AST and ALT less than 3 times upper limit of normal (ULN)
• Bilirubin less than 1.5 times ULN
• Hepatitis B surface antigen negative
• Hepatitis C negative
• Renal
• Creatinine less than 1.8 mg/dL
• Cardiovascular
• No myocardial infarction within the past 6 months
• No New York Heart Association class III or IV heart failure
• No uncontrolled angina
• No severe uncontrolled ventricular arrhythmias
• No electrocardiographic evidence of acute ischemia or active conduction system abnormalities
• No poorly controlled hypertension
• Immunologic
• No active systemic infection requiring treatment
• No prior allergic reaction attributable to compounds containing boron or mannitol
• HIV negative
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception
• No peripheral neuropathy grade 2 or greater
• No diabetes mellitus
• No other serious medical or psychiatric condition that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• More than 6 weeks since prior monoclonal antibody therapy
• No concurrent routine use of colony-stimulating factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])
• No concurrent immunotherapy
• Chemotherapy
• See Disease Characteristics
• More than 4 weeks since prior chemotherapy
• No prior docetaxel
• * Prior paclitaxel allowed
• No other concurrent chemotherapy
• Endocrine therapy
• No concurrent corticosteroids (e.g., prednisone or prednisolone) except dexamethasone as premedication
• Radiotherapy
• More than 4 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery
• More than 4 weeks since prior major surgery
• No concurrent surgery for cancer management or treatment
• Other
• More than 5 years since prior treatment for any other cancer except basal cell skin cancer or carcinoma in situ of the cervix
• More than 4 weeks since prior investigational agents
• No prior bortezomib
• No other concurrent investigational agents
• No other concurrent clinical research study participation
• No other concurrent antineoplastic therapy
• No concurrent routine use of anti-inflammatory drugs, including cyclo-oxygenase inhibitors (e.g., celecoxib or rofecoxib)